Business
Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development
Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended
About this update from Senti Biosciences Holdings, Inc.
[{"type":"image","alt":"Senti Biosciences, Inc.","displaySize":"","headline":null,"caption":"Senti Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":42,"url":"https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LwHg6RoZ4drUhxxgTNKbZQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4576ff302df7a498c5620f46e0596daf","width":166,"height":42}},"lazy":false},{"type":"text","content":"Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: ","length":98,"tagName":"p"},{"type":"text","content":"SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care;All cCR patients maintaining responses, from 4+ to 8+ months ongoing Ongoing enrollment in Phase 1 SENTI-202 study to confirm the preliminary recommended Phase 2 dose (RP2D) followed by disease specific expansion cohorts","length":472,"tagName":"p"},{"type":"text","content":"Logic-Gated cell therapy approach may have the potential for broad liquid and solid tumor applications, providing multiple pipeline expansion opportunities","length":155,"tagName":"p"},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported financial results for the first quarter of 2025 and provided a summary of recent pipeline and corporate highlights.","length":398,"tagName":"p"},{"type":"text","content":"“We continue to be encouraged by our SENTI-202 data and strongly believe in its potential to provide a much-needed treatment option for patients with AML. Notably, our recent data at AACR showed early deep responses seen with SENTI-202 across dose levels, with 4+ to 8+ months of durability noted and growing. We are pleased with the progress made to date, with our team remaining focused on the successful execution of this trial and further SENTI-202 development,” commented Timothy Lu, MD...